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Abstract: Hemolytic uremic syndrome (HUS) is characterized by a triad of symptoms consisting of
hemolytic anemia, thrombocytopenia and acute renal failure. The most common form of HUS is
caused by an infection with Shiga toxin (Stx) producing Escherichia coli bacteria (STEC-HUS), and the
kidneys are the major organs affected. The development of HUS after an infection with Stx occurs
most frequently in children under the age of 5 years. However, the cause for the higher incidence
of STEC-HUS in children compared to adults is still not well understood. Human glomerular
microvascular endothelial cells (HGMVECs) isolated and cultured from pediatric and adult kidney
tissue were investigated with respect to Stx binding and different cellular responses. Shiga toxin-1 (Stx-
1) inhibited protein synthesis in both pediatric and adult HGMVECs in a dose-dependent manner at
basal conditions. The preincubation of pediatric and adult HGMVECs for 24 hrs with TNFα resulted
in increased Stx binding to the cell surface and a 20–40% increase in protein synthesis inhibition in
both age groups. A decreased proliferation of cells was found when a bromodeoxyuridine (BrdU)
assay was performed. A trend towards a delay in endothelial wound closure was visible when
pediatric and adult HGMVECs were incubated with Stx-1. Although minor differences between
pediatric HGMVECs and adult HGMVECs were found in the assays applied in this study, no
significant differences were observed. In conclusion, we have demonstrated that in vitro primary
HGMVECs isolated from pediatric and adult kidneys do not significantly differ in their cell biological
responses to Stx-1.
Keywords: hemolytic uremic syndrome; STEC-HUS; Shiga toxin; human glomerular microvascular
endothelial cells from pediatric and adult origin
1. Introduction
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy with hemolytic
anemia, thrombocytopenia and the kidneys are the major organs affected. Infection with
Shiga toxin (Stx) producing Escherichia coli bacteria (STEC) is one of the causes for the
development of HUS (STEC-HUS) and is mostly seen in children under the age of 5 years [1].
The reason for a higher incidence of STEC-HUS in children compared to adults is still
not understood.
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Infection with STEC mainly occurs by ingestion of contaminated food products [2]
leading to an acute, often bloody diarrhea. Approximately 10–15% of E. coli infected
children will develop HUS [2]. After the transfer from the gut into the bloodstream, Stx
interacts with cells by binding to its main receptor, globotriaosylceramide (Gb3) [3]. Uptake
of the toxin into the cell results in the inhibition of protein synthesis and triggers apoptosis
with cell death as result [4,5].
As Gb3 is the main functional receptor for Stx [3], it was hypothesized that the age-
related incidence of HUS is caused by differential expression levels of Gb3 by the vascular
endothelium of the glomerular capillaries. Studies have shown different levels of Gb3
in different parts of renal tissue with the highest levels present in the cortex [6], but an
age-related difference has not been described yet.
In line with previous published work, we had the chance to isolate and culture primary
human glomerular microvascular endothelial cells (HGMVECs) from pediatric kidneys.
The interaction with Stx-1 was studied and examined in vitro [7] on primary HGMVECs
isolated from two different pediatric kidneys (referred to as pediatric donor I and pediatric
donor II) and from eight adult donors (referred to as adult donor I to adult donor VIII)
with respect to binding, protein synthesis, cell proliferation and migration.
2. Results
2.1. Stx-1 Binding to Pediatric and Adult Primary HGMVECs
To study the binding of Stx to the endothelial cell surface of primary cultured HG-
MVECs derived from two pediatric and four adult kidneys, flow cytometry analysis with
the use of fluorescent labelled Stx-subunit B (Stx-B) was performed. This method is a
reliable and sensitive method for the indirect detection of Gb3 [8]. The proinflammatory cy-
tokine TNFα was used as positive control as it has been described to cause the upregulation
of Gb3 [9]. In addition, TNFα is involved in the pathogenesis of STEC-HUS [10]. As shown
in Figure 1, there was a high donor variation in terms of Stx-B binding on the cell surface of
HGMVECs with the highest binding of Stx-B on HGMVECs derived from adult donor IV.
Binding of Stx-B was low in untreated HGMVECs (control) derived from pediatric donor II
and HGMVECs derived from adult donor III. Incubation of cells with 10 ng/mL of TNFα
for 24 h resulted in an increase of Stx-B binding in all six donors with an average factor of
2.1 (factor 1.8 for pediatric HGMVECs and factor 2.3 for adult HGMVECs). Despite the
results not being significantly different, Stx-B binding was less on the HGMVECs derived
from pediatric tissue compared to the HGMVECs derived from adult tissue under basic
conditions and after TNFα exposure (Figure 1B).
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Figure 1. The binding of Alexa 488 labelled Stx-B on the endothelial cell surface of HGMVECs using flow cytometry. (A) 
Primary HGMVECs from two pediatric donors and four adult donors were incubated without (black bars) or with 10 
Figure 1. The binding of Alexa 488 labelled Stx-B on the endothelial cell surface of HGMVECs using flow cytometry.
(A) Primary HGMVECs from two pediatric donors and four adult donors were incubated without (black bars) or with
10 ng/mL TNFα (grey bars) for 24 h. TNFα upregulated Stx-B binding in all six donors. (B) Results as shown in A expressed
as pediatric vs. adult group. There was no significant difference between the pediatric vs. adult control groups or the
pediatric vs. adult TNFα groups, in their ability to bind Alexa 488-labeled Stx-B (p = 0.145 for ctrl and p = 0.066 for TNFα by
Mann−Whitney test). Mean values and SEM are given. Experiments were performed three times for pediatric donor I and
II, adult donor I and III. Experiments were performed twice for adult donor II and once for adult donor IV.
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2.2. Effect of Stx-1 on Protein Synthesis of Pediatric and Adult Primary HGMVECs
The cytotoxic effect of Stx-1 on primary pediatric and adult HGMVECs was inves-
tigated by using a 3H-leucine incorporation assay/protein synthesis assay. Stx-1 con-
centrations were derived from experiments and results published in the past [7]. Stx-1
at concentrations ranging from 0.001 pM till 1000 pM affected protein synthesis in a
concentration-dependent manner with a 20–40% increase in protein synthesis inhibition
when cells were preincubated with 10 ng/mL of TNFα for 24 h (Figure 2). The protein
synthesis of HGMVECs derived from two pediatric tissues (pediatric I and II) incubated
with 1000 pM of Stx1 for 24 h decreased by 40% in the control group and with 80% in
cells prestimulated with TNFα (Figure 2). In contrast, the protein synthesis of primary
HGMVECs derived from three adult tissues (adult V, VI, VII) incubated with 1000 pM of
Stx1 for 24 h decreased by 75% in the control group and 95% in cells prestimulated with
TNFα (Figure 2). In summary, primary HGMVECs from adult kidney tissues showed a
tendency towards a higher sensitivity for Stx-1 in terms of protein synthesis inhibition
compared to HGMVECs derived from pediatric tissues.
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Figure 2. The effect of Stx-1 on the protein synthesis of primary HGMVECs measured by a 3H-leucine incorporation assay
in pediatric HGMVECs from two donors and adult HGMVECs from three donors. Stx-1 at concentrations ranging from
0.001 pM to 1000 pM in control or cells preincubated with TNFα 10 ng/mL for 24 h were used. An increase of 20–40% in
protein synthesis inhibition was measured when cells were preincubated with 10 ng/mL of TNFα for 24 h, however no
significant difference by ANOVA between adult and pediatric conditions was found (p = 0.712). Mean values and SEM are
given. Experiments were performed three times with HGMVECs from pediatric donor I and once with HGMVECs from
pediatric donor II. Experiments were performed twice with HGMVECs from adult donor VII, once with adult donor V and
once with adult donor VI.
2.3. Effect of Stx-1 on the Proliferation of Pediatric and Adult HGMVECs
The effect of Stx-1 on the proliferation of HGMVECs was studied using a BrdU
proliferation assay. BrdU is incorporated into the cell during DNA synthesis in proliferating
cells [11]. The proliferation of HGMVECs was investigated after the preincubation of cells
with 10 ng/mL of TNFα and incubation of cells with 0.1 to 1000 pM Stx-1 for 24 h. As
Int. J. Mol. Sci. 2021, 22, 5615 4 of 10
depicted in Figure 3, the proliferation pattern is similar in primary pediatric and adult
HGMVECs. TNFα alone decreased cell proliferation by 27–33%, compared to control cells.
Preincubation with 10 ng/mL of TNFα for 24 h and incubation with 0.1, 10 or 1000 pM of
Stx-1 over a time period of 24 h decreased cell proliferation in a concentration-dependent
manner. A concentration of 0.1 pM of Stx-1 with TNFα decreased cell proliferation by
38–42 % in both pediatric and adult HGMVECs, while a concentration of 1000 pM Stx-1
with TNFα decreased cell proliferation by 64% in pediatric HGMVECs and 73% in adult
HGMVECs as compared with control cells. No significant difference in proliferation was
established between pediatric and adult HGMVECs when statistics were applied for every
single condition. However, a concentration of 10 pM Stx-1 or 1000 pM Stx-1 resulted in less
proliferation of adult HGMVECs compared to pediatric HGMVECs. This is in line with the
results of the protein synthesis assay.
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Figure 3. The effect of Stx-1 on the proliferation of HGMVECs by using a BrdU proliferation assay. Cells were incubated for
24 h with TNFα 10 ng/mL alone or preincubated with TNFα and incubated with 0.1, 10 and 1000 pM Stx-1. No significant
difference by Mann−Whitney test was found between pediatric and adult HGMVECs for any single condition. Mean values
and SEM are given. Experiments were executed in duplicate. Experiments wer performed five times with HGMVECs from
pediatric dono I and pediatric donor II. Experiments were performed five times with HGMVECs from adult don rs III,
three times with HGMVECs from adult donor I and twice with HGMVECs from adult donors II, IV and VIII.
2.4. Effect of Stx-1 on the Migration of Pediatric and Adult HGMVECs
The effect of Stx-1 on the migration of HGMVECs was investigated by using an
endothelial wound closure assay. A concentration of 10 pM Stx-1 was chosen as this
concentration resulted in approximately 50% decreased protein synthesis in HGMVECs
preincubated with TNFα 10 ng/mL as shown in Figure 2. TNFα alone had no significant
effect on endothelial cell migration. A significant delay in wound closure was only mea-
sured after 8 h and 12 h of incubation between adult HGMVECs in the control group or
preincubated with TNFα when compared with cells preincubated with TNFα and 10 pM
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Stx-1 (Figure 4). No significant difference was detected when the wound closures of pedi-
atric and adult HGMVECs were compared. However, after 12 h of wound closure, TNFα in
combination with 10 pM Stx-1 showed, although not significant, about 10% delay in wound
closure when pediatric HMVECs were used and a significant 20% delay when adult HG-
MVECs were used and compared to their own control group. This is in line with the results
found in the protein synthesis assay (Figure 2) and the results of the proliferation assay
(Figure 3) where adult HGMVECs displayed a tendency to a higher sensitivity for Stx-1.
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3. Discussion
In this study, the interaction of Stx-1 with primary HGMVECs derived from pedi-
atric and adult kidney tissue was examined by studying binding, protein synthesis, cell
proliferation and migration. There was no difference between the binding of Stx-B to
pediatric-derived HGMVECs as compared to adult HGMVECs. In both pediatric and adult
HGMVECs, preincubation with TNFα led to increased Stx binding. Stx-1 was cytotoxic
for HGMVECs in a dose-dependent manner, and TNFα increased the protein synthesis
inhibition by 20–40%. Decreased proliferation of HGMVECs in a concentration-dependent
manner was measured when cells were incubated with TNFα alone or when incubated with
Stx-1 in combination with pretreatment with TNFα. There was no significant difference in
pediatric cell migration after treatment with Stx-1, however a clear trend towards a delay
in wound healing was visible. Even though an increased sensitivity of adult HGMVECs
for Stx-1 compared to pediatric HGMVEC was seen at increasing concentrations of Stx-1,
no significant differences were observed.
It was suggested that the glomerular endothelium of young children expresses higher
levels of Gb3 compared to the glomerulus of adults. We have expanded on studies pub-
lished in the past and used primary HGMVECs derived from two pediatric kidney tissues.
Primary cells most closely represent the tissue of origin and are not genetically modified.
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They have not been used before to study Gb3 levels and primary pediatric cells are scarce,
which make them a unique tool to use in the current examination.
Lingwood et al. compared the binding of Stx-B between the kidney tissue of infants
and adults [6,12]. They found that Stx-B bound to the glomeruli of infants < 2 years and
not to the glomeruli of adults [12]. It should be noted that, for the most part, kidney
sections of steroid sensitive nephrotic syndrome (SSNS) patients were examined, which
have been in contact with systemically and locally released cytokines which might result in
higher levels of Gb3 and more Stx-B binding in different parts of the kidneys. In another
publication from Boyd et al., they investigated the Gb3 content and Stx-B binding to human
kidneys as a function of age [6]. Although they only had two samples of children and five
samples of adults, the levels of Stx-B binding increased significantly in adult kidneys [6].
However, it must be noted that small amounts of a second Stx-binding glycolipid were
detected in their experiments. This glycolipid terminated in the gal-α1-4gal structure. This
structure is necessary for the binding of the toxin and thus may have played a role in the
increments found [6]. Ergonul et al. compared frozen renal sections from subjects aged
between 6 months to 85 years and showed that the pattern of Stx-1 binding was identical
between the different age groups [13]. It is clear that we cannot compare our results of
in vitro endothelial cell monoculture experiments with the above-mentioned pathology
studies as they do not mimic the same cellular interactions and extracellular environment.
The pediatric HGMVECS used in this study were isolated from kidneys of children
under the age of 3 years, not suitable for transplantation, and are not representable for
the glomerular endothelium of STEC-HUS patients. It is not feasible to obtain and cul-
ture HMGVECS from STEC-HUS patients as mostly no biopsy is clinically needed and
not preferable, due to thrombocytopenia. However, it is possible to examine the host
characteristics of STEC-HUS patients using blood outgrowth endothelial cells (BOECs)
derived from pediatric patients with a history of STEC-HUS. BOECs are not derived from
the kidneys of patients, nonetheless they do represent the endothelial characteristics and
(epi)genetical background of the donor. In a recently published study, BOECs isolated from
STEC-HUS patients showed no differences [14]. It is most likely that other factors, such as
cytokines, chemokines, and circulating blood cells activated by the gastrointestinal STEC
infection, activate the glomerular endothelial cells and their surrounding environment to a
proinflammatory state.
The variation in results upon Stx incubation between the cell cultures of various
donors was most likely multifactorial and dependent on the expression of Gb3 on the cell
surface. It is known that Gb3 expression at the cell surface can vary and depends on cell
confluency as well as passages of primary cells used in the experiments. Subconfluent
monolayers of HGMVECs as well as HUVECs show a higher expression of Gb3 on the
surface leading to a higher cytotoxicity of Stx as compared to confluent monolayer of
cells [15]. Van Setten et al. [7] showed that a confluent layer of HGMVECs only became
susceptible for Stx-1 after preincubation with TNFα. Van Setten et al. [7] maintained cells
for five days in a confluent state, while we treated the cells with Stx-1 the first day after
reaching 80−100 % confluency.
Blood cells as well as other glomerular cells are considered to play a role in the
pathogenesis of disease. Ichimura [16] investigated bacterial responses under the influence
of different concentrations of nitric oxide (NO). Their group suggested that nitric oxide
generation in macrophages might stimulate the production of Stx. It has also been reported
that Stx decreases the secretion of vascular endothelial growth factor (VEGF) [17]. VEGF is
a potent angiogenic factor mainly produced by podocytes, that induces the formation of
fenestrations in the endothelium of the glomerulus [18]. Decreased VEGF levels caused
glomerular thrombotic microangiopathy (TMA) in mice [18]. Therefore, VEGF may play a
role in the pathogenesis of STEC-HUS as HUS falls under the clinical picture of TMAs.
Another pathway which may play a role in pathogenesis is the complement system,
a system which is part of innate immunity. Overactivation of this system is known to be
the main driver of disease in atypical HUS [19]. It has been shown that Stx binds factor H
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(FH), with delayed and reduced co-factor activity as result [20]. Furthermore, Stx caused
downregulation of the complement inhibitor CD59 on tubular epithelial and glomerular
endothelial cells [21] and from a clinical perspective, induced complement protein levels
in patients with STEC-HUS at the time of hospital admission have been measured [22,23].
Among other publications, these studies suggest complement activation as a component of
the pathophysiology of STEC-HUS.
Still, at the moment, no model is available that recapitulates all the features of STEC
infection and Gb3 expression is different in the kidneys from animals as compared to
humans [24,25]. Future experiments using various kidney cells and/or kidney organoids in
a co-culture system would bring us closer to the actual situation inside the body. Another
arsenal available to study the pathophysiology of diseases is animal models.
In conclusion, no differences in cell biological responses after Stx-1 exposure to primary
HGMVECs from pediatric and adult origin were established. Other extrinsic or (epi)genetic
factors might contribute to the sensitivity of the glomerular endothelium of children and
the use of more sophisticated models, would help to gain a better understanding about the
pathophysiology of this rare disease.
4. Materials and Methods
4.1. Ethics
This study was approved by the Medical Ethical Review Board of the Radboudumc,
Nijmegen, The Netherlands. Written informed consent was obtained with a signature from
parents/legal guardians or controls whose HGMVECs were used in this study. This study
was executed in keeping with the regulations of the Declaration of Helsinki.
4.2. Isolation and Purification of Human Glomerular Microvascular Endothelial Cells
(HGMVECs)
Studies were performed with human pediatric kidney tissue obtained from two
kidneys of pediatric donors between the age of 2 and 3 years as well as eight healthy
adult donors that were not suitable or disapproved for transplantation. The isolation and
purification of the HGMVECs was carried out as previously described [7]. Briefly, glomeruli
were isolated by dissecting the cortex followed by a gradual sieving procedure. Because
the glomeruli of children are considerably smaller than those of adults, glomeruli were
collected on top of smaller size screens (38, 53, 90 and 108 µm). Subsequently, glomeruli
were digested with 0.1% (w/v) collagenase type 2 CLS (Worthington, NJ, USA) for 2 h at
37 ◦C. Glomerular remnants were resuspended in complete medium which consisted of
M199 (Gibco Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat
inactivated newborn calf serum (Gibco Thermo Fisher Scientific, Waltham, MA, USA),
10% heat inactivated human serum (Innovative Research, Novi, MI), 2 mmol/L glutamine
(Gibco Thermo Fisher Scientific, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco
Thermo Fisher Scientific, Waltham, MA, USA), 5 U/mL heparin (Leo Pharmaceuticals,
Weesp, The Netherlands) and 150 mg/L of endothelial cell growth factor (extracted from
bovine brains as described by Maciag et al. [26]) and plated on gelatin coated plates
(Corning Incorporated, Kennebunk, ME, USA). Attachment occurred within one or two
days after which endothelial and epithelial cells started to grow out with high proliferation
rates. Primary outgrowths were selectively trypsinized and filtrated through a 38 µm
sieve to enrich HGMVECs. HGMVECs were specifically collected by performing an
immunomagnetic separation technique using a monoclonal antibody against platelet cell
adhesion molecule-1 (PECAM-1) as an endothelial specific antibody. Highly purified
populations of pediatric HGMVECs were obtained by repeating the immunomagnetic
separation technique once or twice. Cells with 80–100 % confluency, passage 6–11, were
used for experiments.
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4.3. Reagents
Shiga toxin type 1 (Stx-1) was ordered from Phoenix Lab (Tufts Medical Center, Boston,
MA). The amount of LPS remaining in the preparations was determined as <0.01 endotoxin
units per mL. Alexa 488 labeled Shiga toxin subunit B (Stx-B) was kindly provided by C.
Lingwood, The Hospital for Sick Children, Toronto, ON, Canada.
4.4. Flow Cytometry
HGMVECs were seeded in 24-well plates. Cells were incubated with or without
10 ng/mL of TNFα (Roche Diagnostics, Indianapolis, IN, USA) for 24 h. Next, cells were
fixed with 0.5% PFA/PBS for 5 min at room temperature. Cells were incubated with Alexa
488-labeled Stx-B at a concentration of 5 ug/mL and stored for 30 min at 4 ◦C protected from
light. Cells were trypsinized, suspended in 10% FBS/PBS, spun down by centrifugation
and resuspended in 0.1% BSA/PBS. Read out was done with the use of a CytoFlex Flow
Cytometer (Beckman Coulter, Brea, CA, USA).
4.5. Protein Synthesis by Radiolabeled 3H-Leucine Incorporation Assay
HGMVECs were seeded in 24-well plates. Cells were prestimulated with or without
10 ng/mL of TNFα for 24 h and incubated with increasing concentrations of Stx-1 in a
range of 0.001−1000 pM for 24 h together with 3H-leucine (PerkinElmer, Boston, MA, USA).
The 3H-leucine incorporation assay was further carried out as previously described [14].
4.6. Bromodeoxyuridine (BrdU) Proliferation Assay
HGMVECs were seeded in 96-well plates and preincubated with 10 ng/mL TNFα for
24 h. Stx-1 in a concentration of 0.1−1000 pM in combination with 10 µM BrdU (Sigma-
Aldrich, St. Louis, MO, USA) was added and stored in a 37 ◦C incubator with 5% CO2 for
24 h. The BrdU assay was performed according to manufacturer’s protocol (Sigma-Aldrich,
St. Louis, MO, USA).
4.7. Endothelial Wound Closure Assay
HGMVECs were seeded in 24-well plates and preincubated with 10 ng/mL TNFα
for 24 h. After 24 h, fresh media with or without 10 pM Stx1 was added, and a manual
scratch wound was created with a 200 uL pipette tip. Next, a previously published protocol
was followed [14,27]. Images were captured after timepoint 0, 4, 8 and 12 h with a Zeiss
Axiovert 25 inverted transmitted light microscope (Zeiss, Oberkochen, Baden-Württemberg,
Germany) in combination with a Canon EOS 1000D camera (Canon, Tokio, Japan). Analysis
of the images was performed with the use of ImageJ software version 1.51n (LCOI, Madison,
WI, USA).
4.8. Statistical Analysis
Data were analyzed by nonparametric Mann−Whitney test or Kruskal−Wallis test. A
p-value of <0.05 was set as statistically significant. All statistical analysis were performed
using GraphPad Prism version 5.03 (GraphPad Software, La Jolla, CA, USA) or SPSS (IBM,
Amsterdam, Netherlands). Data are expressed as mean ± SEM.
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